Lantheus (LNTH) Scheduled to Post Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $1.34 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The firm had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Lantheus Stock Performance

NASDAQ LNTH opened at $65.21 on Thursday. Lantheus has a 1-year low of $50.20 and a 1-year high of $100.85. The company has a market capitalization of $4.47 billion, a P/E ratio of 14.01 and a beta of 0.53. The business has a 50 day moving average price of $61.13 and a 200 day moving average price of $62.73. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 94,545 shares of company stock worth $6,169,936. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

LNTH has been the subject of several recent research reports. JMP Securities reissued a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Finally, Truist Financial reissued a “buy” rating and issued a $82.00 price target (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $104.71.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.